Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SERPINE1 | P05121 | 7/20 | 0.64 |
| ▸ | PLA2G2A | P14555 | 3/20 | 0.64 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.55 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.55 |
| ▸ | PPARG | P37231 | 3/20 | 0.55 |
| ▸ | PPARD | Q03181 | 3/20 | 0.55 |
| ▸ | PPARA | Q07869 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.51 |
| ▸ | CNR2 | P34972 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7679573 | 0.96 | SERPINE1 (0.59) | SERPINE1PLA2G2ALTB4RLTB4R2PPARG | |
| SCHEMBL3386836 | 0.90 | LTB4R (0.66) | SERPINE1PLA2G2ALTB4RLTB4R2PPARG | |
| SCHEMBL5894096 | 0.86 | PLA2G2A (0.56) | SERPINE1PLA2G2ALTB4RLTB4R2PPARG | |
| SCHEMBL7680496 | 0.83 | SERPINE1 (0.54) | SERPINE1PLA2G2ALTB4RLTB4R2PPARG | |
| SCHEMBL27751714 | 0.81 | PPARD (0.54) | PLA2G2ALTB4RLTB4R2PPARGPPARD | |
| SCHEMBL4942305 | 0.80 | SERPINE1 (0.81) | SERPINE1PLA2G2ALMNAADORA1CNR2 | |
| SCHEMBL28462854 | 0.80 | LTB4R (0.52) | SERPINE1PLA2G2ALTB4RLTB4R2PPARG | |
| SCHEMBL3206115 | 0.80 | PLA2G2A (0.57) | SERPINE1PLA2G2APPARD | |
| SCHEMBL27732143 | 0.80 | CNR1 (0.49) | SERPINE1LTB4RLTB4R2PPARGPPARD | |
| SCHEMBL5625905 | 0.79 | ADORA1 (0.78) | SERPINE1LMNAALDH1A1ADORA1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7674818-B2 | Aryl, aryloxy, alkyloxy substituted 1H-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | WYETH LLC (US) | 2010-03-09 | — | — | US | claimed |
| CN-101384256-A | PAI-1 Inhibitors for the Treatment of Muscle Conditions | WYETH CORP (US) | 2009-03-11 | — | — | CN | claimed |
| EP-2010171-A2 | INHIBITORS OF PAI-1 FOR TREATMENT OF MUSCULAR CONDITIONS | Wyeth a Corporation of the State of Delaware (US) | 2009-01-07 | — | — | EP | claimed |
| EP-1569901-B1 | ARYL, ARYLOXY, AND ALKYLOXY SUBSTITUTED i 1H /i -INDOL-3-YL GLYOXYLIC ACID DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) | WYETH CORP (US) | 2008-10-15 | — | — | EP | claimed |
| US-20070259922-A1 | Aryl, aryloxy, alkyloxy substituted 1H-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | WYETH (US) | 2007-11-08 | — | — | US | claimed |
| WO-2007098278-A2 | INHIBITORS OF PAI-1 FOR TREATMENT OF MUSCULAR CONDITIONS | WYETH (US) | 2007-08-30 | — | — | WO | claimed |
| US-20070203220-A1 | Inhibitors Of PAI-1 For Treatment Of Muscular Conditions | WYETH (US) | 2007-08-30 | — | — | US | claimed |
| CN-1723198-A | Aryl, aryloxy, and alkyloxy substituted 1h-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | WYETH CORP (US) | 2006-01-18 | — | — | CN | claimed |
| EP-1569901-A2 | ARYL, ARYLOXY, AND ALKYLOXY SUBSTITUTED i 1H /i -INDOL-3-YL GLYOXYLIC ACID DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) | Wyeth (US) | 2005-09-07 | — | — | EP | claimed |
| US-20040138283-A1 | Aryl, aryloxy, and alkyloxy substituted 1H-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | WYETH (US) | 2004-07-15 | — | — | US | claimed |
| WO-2004052854-A2 | ARYL, ARYLOXY, AND ALKYLOXY SUBSTITUTED 1H-INDOL-3-YL GLYOXYLIC ACID DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) | WYETH (US) | 2004-06-24 | — | — | WO | claimed |
| US-7674818-B2 | Aryl, aryloxy, alkyloxy substituted 1H-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | WYETH LLC (US) | 2010-03-09 | — | — | US | disclosed |
| CN-101384256-A | PAI-1 Inhibitors for the Treatment of Muscle Conditions | WYETH CORP (US) | 2009-03-11 | — | — | CN | disclosed |
| EP-2010171-A2 | INHIBITORS OF PAI-1 FOR TREATMENT OF MUSCULAR CONDITIONS | Wyeth a Corporation of the State of Delaware (US) | 2009-01-07 | — | — | EP | disclosed |
| EP-1569901-B1 | ARYL, ARYLOXY, AND ALKYLOXY SUBSTITUTED i 1H /i -INDOL-3-YL GLYOXYLIC ACID DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) | WYETH CORP (US) | 2008-10-15 | — | — | EP | disclosed |
| US-7259182-B2 | Deep vein thrombosis, noninsulin dependent diabetes, atherosclerosis, and pulmonary fibrosis treatment; cardiovascular and brain disorders | WYETH (US) | 2007-08-21 | — | — | US | disclosed |
| CN-1723198-A | Aryl, aryloxy, and alkyloxy substituted 1h-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | WYETH CORP (US) | 2006-01-18 | — | — | CN | disclosed |
| EP-1569901-A2 | ARYL, ARYLOXY, AND ALKYLOXY SUBSTITUTED i 1H /i -INDOL-3-YL GLYOXYLIC ACID DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) | Wyeth (US) | 2005-09-07 | — | — | EP | disclosed |
| US-20040138283-A1 | Aryl, aryloxy, and alkyloxy substituted 1H-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | WYETH (US) | 2004-07-15 | — | — | US | disclosed |
| WO-2004052854-A2 | ARYL, ARYLOXY, AND ALKYLOXY SUBSTITUTED 1H-INDOL-3-YL GLYOXYLIC ACID DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) | WYETH (US) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203220-A1 | Inhibitors Of PAI-1 For Treatment Of Muscular Conditions | SERPINE1, SERPINB1, SERPINC1 | SERPINE1 1/4885PLA2G2A 1905/4885LTB4R 2056/4885 |
| US-20040138283-A1 | Aryl, aryloxy, and alkyloxy substituted 1H-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | SERPINE1, PLAT, SERPINC1 | SERPINE1 1/4885PLA2G2A 1523/4885LTB4R 418/4885 |
| US-20070259922-A1 | Aryl, aryloxy, alkyloxy substituted 1H-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | SERPINE1, SERPINC1, PLAT | SERPINE1 1/4885PLA2G2A 1548/4885LTB4R 408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.